[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.146.179.146. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Medical News & Perspectives
April 20, 2011

FDA Expands Age Range for Shingles Vaccine

JAMA. 2011;305(15):1526. doi:10.1001/jama.2011.495

Vaccination to help prevent shingles now is available for adults aged 50 to 59 years as well as for those aged 60 years and older. The US Food and Drug Administration (FDA) announced its approval of the expanded age range for the vaccine, marketed as Zostavax, in late March.

“The availability of Zostavax to a younger age group provides an additional opportunity to prevent this often painful and debilitating disease,” Karen Midthun, MD, director of the FDA's Center for Biologics Evaluation and Research, said in a statement.

First Page Preview View Large
First page PDF preview
First page PDF preview
×